Olodaterol (Striverdi Respimat) for COPD

Medical Letter on Drugs and Therapeutics

Volumn 57, Issue 1459, 2015, Pages 1-3

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ARFORMOTEROL; BUDESONIDE PLUS FORMOTEROL; CYTOCHROME P450 2C9; DIURETIC AGENT; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPROTEIN P INHIBITOR; INDACATEROL; MONOAMINE OXIDASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; OLODATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; BENZOXAZINE DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIARRHEA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INSOMNIA; LUNG FUNCTION; META ANALYSIS (TOPIC); PREGNANCY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; TACHYCARDIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANIMAL; CLINICAL TRIAL (TOPIC); PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ANIMALS; BENZOXAZINES; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84921941076     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Indacaterol (Arcapta Neohaler) for COPD. Med Lett Drugs Ther 2012; 54:33.
2. Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD. Med Lett Drugs Ther 2014; 56:30.
3. Breo Ellipta: an inhaled fluticasone/vilanterol combination for COPD. Med Lett Drugs Ther 2013; 55:69.
4. Drugs for asthma and COPD. Treat Guidel Med Lett 2013; 11:75.
5. GJ Feldman et al. The 24-h FEV1 time profile of olodaterol once daily via Respimat and formoterol twice daily via Aerolizer in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus 2014; 3:419.
6. GT Ferguson et al. Efficacy and safety of olodaterol once daily delivered via Respimat in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9:629.
7. A Koch et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9:697.
8. NS Roskell et al. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis 2014; 9:813.